A phase 2, randomized, double blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of varying loading and maintenance dosing regimens of ISIS 301012 [mipomersen sodium] administered to hypercholesterolemic subjects

Trial Profile

A phase 2, randomized, double blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of varying loading and maintenance dosing regimens of ISIS 301012 [mipomersen sodium] administered to hypercholesterolemic subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jan 2008 The actual completion date for this trial is now 1 Nov 2007.
    • 24 Jan 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top